Epidemiology of Gout in French Polynesia (TOPATA)
Primary Purpose
Gout
Status
Completed
Phase
Not Applicable
Locations
French Polynesia
Study Type
Interventional
Intervention
Epidemiological study
Sponsored by
About this trial
This is an interventional other trial for Gout focused on measuring Gout, French Polynesia, Epidemiology
Eligibility Criteria
Inclusion Criteria:
- Living in Tahiti, Moorea, Tahaa-Raiatea, Tikehau, Nuku Hiva, Mangareva, Rurutu
- Agreeing to participate in the study
Exclusion Criteria:
- Homeless
- Living in communities (military camp, hospices, university residence, ...)
- Unable to answer questionnaires
- Under guardianship
Sites / Locations
- Centre Hospitalier de la Polynésie Française
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Epidemiological study
Arm Description
Outcomes
Primary Outcome Measures
Gout Prevalence
Measure of gout prevalence
Secondary Outcome Measures
Diagnosis of Hyperuricemia
Diagnosed when uricemia is higher than 360 µmol/l
Genome wide analysis for identification of genetic variants linked to gout
Analysis of the genetic determinants of gout and hyperuricemia in French Polynesia via a pan-genomic analysis using complete and then rapid sequencing techniques
HLA B58:01 allele prevalence
Multiple correlation between renal failure, diabetes, gout and cardiovascular comorbidities
The association between cardiovascular comorbidities/renal failure/diabetes and gout will be investigated using a multivariate logistic regression model.
Multiple correlation between renal failure, diabetes, hyperuricemia and cardiovascular comorbidities
The association between cardiovascular comorbidities/renal failure/diabetes and hyperuricemia will be investigated using a multivariate logistic regression model.
Full Information
NCT ID
NCT04812886
First Posted
March 17, 2021
Last Updated
September 29, 2021
Sponsor
Lille Catholic University
Collaborators
Variant Bio, Inc., University of Birmingham, University of San Diego, Ministry of Health, French Polynesia
1. Study Identification
Unique Protocol Identification Number
NCT04812886
Brief Title
Epidemiology of Gout in French Polynesia
Acronym
TOPATA
Official Title
Gout in French Polynesia: Epidemiology and Comorbidities, Genetic Causes and Prevalence of HLA B58:01
Study Type
Interventional
2. Study Status
Record Verification Date
September 2021
Overall Recruitment Status
Completed
Study Start Date
April 29, 2021 (Actual)
Primary Completion Date
August 16, 2021 (Actual)
Study Completion Date
August 16, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lille Catholic University
Collaborators
Variant Bio, Inc., University of Birmingham, University of San Diego, Ministry of Health, French Polynesia
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Gout is a chronic disease caused by the deposit of monosodium urate (MSU) crystals in body tissues secondary to hyperuricemia. Patients with gout suffer severe attacks of acute joint pain. As the disease progresses, the joint pain becomes chronic and associated with disabling and deformative manifestations called tophi. Gout is strongly associated with various comorbidities including cardiovascular disease and chronic kidney failure. Gout is a very common disease, affecting 0.9% of the adult population in France and nearly 4% of the North-American population. Data from New Zealand show a particularly high prevalence of gout among Polynesians (minority populations in New Zealand and other islands of the South Pacific) that would be explained by genetic susceptibility and frequently intertwined with metabolic diseases. Recent findings obtained from the Polynesian population in New Caledonia disclose high prevalence figures close to 7%, a level expected to be confirmed by an epidemiology study that will be conducted in parallel with the present study and designed to determine the precise prevalence of gout in French Polynesia and the most frequently associated genetic variants.
Detailed Description
International genomic studies conducted in populations with hyperuricemia and gout have identified a number of associated alleles. The strength of the association between a given allele and gout (or hyperuricemia) provides an indication of the importance of the encoded protein in disease pathogenesis. It was in this way that the development of gout was found to depend on renal urate transporters that were subsequently targeted by new uricosuric therapies.
Overall, the search for gout-associated genes has mostly been done in the general European population and revealed a small number of candidate loci. Most of these only contribute a small amount to the heritability for gout susceptibility, suggesting that additional genes and mechanisms of genetic influence are yet to be discovered. A common feature of Genome-Wide Association studies done so far is that usually large sample sizes are required in order to detect differences in allele frequencies and their contribution to different traits between test groups. The Polynesian population of French Polynesia possesses characteristics that make it particularly attractive to carry out population-based genetic research. Historical records indicate that the Polynesians of Tahiti and surrounding islands originate from a small founder population that has undergone a number of bottlenecks, eventually becoming a genetically homogenous population with a fairly high degree of consanguinity. The combination of a historic founder event, continued isolation and recent expansion are all ideal properties for a Genome Wide Association Study, as they ensure that 1) population stratification will be easy to correct when performing association tests and 2) there are likely high-effect variants that were kept at low frequency in mainland Europe due to negative selection but rose to high frequencies in the Polynesians via the increase in genetic drift or selection through adaptation to a specific environment and diet. Therefore, it is plausible that rare variants with large effect on health-related quantitative traits may be more easily detectable in Polynesians, even with much smaller sample sizes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gout
Keywords
Gout, French Polynesia, Epidemiology
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
1088 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Epidemiological study
Arm Type
Experimental
Intervention Type
Other
Intervention Name(s)
Epidemiological study
Intervention Description
Questionnaires (quality of life, gout, life habit, comorbidities) anthropometrics and health measures DNA analysis RNA analysis Metabolomic analysis
Primary Outcome Measure Information:
Title
Gout Prevalence
Description
Measure of gout prevalence
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Diagnosis of Hyperuricemia
Description
Diagnosed when uricemia is higher than 360 µmol/l
Time Frame
6 months
Title
Genome wide analysis for identification of genetic variants linked to gout
Description
Analysis of the genetic determinants of gout and hyperuricemia in French Polynesia via a pan-genomic analysis using complete and then rapid sequencing techniques
Time Frame
6 months
Title
HLA B58:01 allele prevalence
Time Frame
6 months
Title
Multiple correlation between renal failure, diabetes, gout and cardiovascular comorbidities
Description
The association between cardiovascular comorbidities/renal failure/diabetes and gout will be investigated using a multivariate logistic regression model.
Time Frame
6 months
Title
Multiple correlation between renal failure, diabetes, hyperuricemia and cardiovascular comorbidities
Description
The association between cardiovascular comorbidities/renal failure/diabetes and hyperuricemia will be investigated using a multivariate logistic regression model.
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Living in Tahiti, Moorea, Tahaa-Raiatea, Tikehau, Nuku Hiva, Mangareva, Rurutu
Agreeing to participate in the study
Exclusion Criteria:
Homeless
Living in communities (military camp, hospices, university residence, ...)
Unable to answer questionnaires
Under guardianship
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tristan Pascart, MD, PhD
Organizational Affiliation
GHICL
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre Hospitalier de la Polynésie Française
City
Pirae
ZIP/Postal Code
98713
Country
French Polynesia
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Epidemiology of Gout in French Polynesia
We'll reach out to this number within 24 hrs